[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"extracorporeal-membrane-oxygenation-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:extracorporeal-membrane-oxygenation-complication":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,46,79,119,147,170,197,222,243,269,292,313,342,365,386,410,431,466,496,523,545,575,595,620],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100552185","ecmo-abi-detection-with-hyperfine-100552185",false,"NCT06469801","ECMO ABI Detection With Hyperfine","Low-Field Bedside MRI for Detection of Acute Brain Injury in Pediatric Extracorporeal Membrane Oxygenation","Inclusion Criteria\n\n* Participants that will be or are admitted to the Pediatric Intensive Care Unit, Cardiac Intensive Care Unit, or the Neonatal Intensive Care Unit\n* Ages 0-17 years\n* Participants that are at high risk for undergoing ECMO or are currently undergoing venovenous or venoarterial ECMO\n\n  • High risk participants include, but are not limited to:\n* Undergoing cardiac surgery\n* Congenital heart disease\n* Congenital diaphragmatic hernia\n* Refractory hypoxemic and\u002For hypercarbic respiratory failure\n* Vasoactive-refractory shock\n\nExclusion Criteria\n\n* Pregnancy\n* Active implants such as:\n\n  * Pacemaker\n  * Implanted defibrillator\n  * Implanted insulin pump\n  * Deep brain stimulator\n  * Vagus nerve stimulator\n  * Cochlear implant\n  * Programmable shunt\n* MRI incompatible surgical hardware (e.g., staples, screws, etc.)\n* Metal-containing tattoos or permanent make-up on head or neck\n* Suspected metal in eye, e.g.,\n* Former or current welders, metal workers, or individuals with a metal injury\n* Metal shrapnel\n* Passive implants are considered MRI-conditional","ALL","0 Days","17 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The primary objective is to characterize the prevalence and type of ABI following cannulation for pediatric patients who require ECMO support. The secondary objective is to describe the time course and rates of ABI using ultralow-field bedside MRI relative to both duration of ECMO support and clinical imaging obtained in routine care of pediatric ECMO patients.",[27,28,29,30],"Acute Brain Injury","Extracorporeal Membrane Oxygenation Complication","Hypoxia-Ischemia, Brain","Stroke, Acute",[32],"Pediatric","RECRUITING","2026-06-30",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":39,"type":37},"2024-07-23",{"date":41,"type":21},"2027-12-01",{"name":43,"class":44},"Children's Mercy Hospital Kansas City","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":45},"100639802","platelets-and-extracorporeal-membrane-oxygenation-veno-venous-100639802","NCT07580469","Platelets and Extracorporeal Membrane Oxygenation Veno-venous","Study of PLATelet Functions and Risk Factors for Hemorrhagic Complications in Patients on Extracorporeal Membrane Oxygenation Veno-venous: Prospective Monocentric Cohort","PLAT-VV-ECMO","Inclusion Criteria:\n\n* Adults aged ≥ 18 years\n* No objection to participation in the study, obtained from a relative or trusted person; if no relative is available, inclusion under emergency procedure (pending patient or relative non-opposition)\n* Patients requiring admission to the general intensive care unit of Hôpital Rangueil for venovenous ECMO\n* Equipped with an arterial catheter for blood sampling\n* Ability to undergo the 4 blood draws relevant to the study\n* Receiving therapeutic anticoagulation with unfractionated heparin\n* Enrolled in a social security program or equivalent\n* No measures for Limitation and Withdrawal of Therapy have been implemented\n\nExclusion Criteria:\n\n* Minors\n* Patients under court-appointed guardianship or conservatorship\n* Pregnant or breastfeeding women\n* Hematological disease (leukemia, lymphoma) or constitutional thrombocytopenia\n* Platelet transfusion within 7 days prior to enrollment\n* Indication for immediate emergency ECMO preventing blood sampling before placement\n* Post-cardiotomy\n* Patient on antiplatelet therapy\n* Severe thrombocytopenia \\\u003C50 G\u002FL\n* Other invasive mechanical support such as Impella®, intra-aortic balloon pump, or Left Ventricular Assist Device (LVAD)","18 Years",{"count":56,"type":21},40,"OBSERVATIONAL","In severe lung or heart disease, ExtraCorporeal Membrane Oxygenation (ECMO) may be used temporarily and can be responsible for major haemorrhagic complications. Thrombocytopenia and possibly thrombopathy promote bleeding. The primary objective is to characterize platelet dysfunction by aggregometry tests over time. Secondarily, investigators seek a correlation between haemorrhagic complications at day 10 and markers of platelet action and dysfunction; also, with the level of anticoagulation and inflammation by biomarkers.",[28,60,61,62],"Hemorrhage","Blood Platelet Disorder","Thrombosis",[64,65,66,67,68],"VV-ECMO","Platelets","Thrombopathy","thrombo-haemorrhagic complications","thrombo-inflammation","NOT_YET_RECRUITING","2026-06-24",{"date":72,"type":37},"2026-06-29",{"date":74,"type":21},"2026-09",{"date":76,"type":21},"2028-12-31",{"name":78,"class":44},"University Hospital, Toulouse",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":98,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100556548","phase-3-recommend-platform-trial-100556548","NCT06526533","RECOMMEND Platform Trial","Generating New Evidence to Reduce Major Complications to Improve the Safety and Efficacy of ECMO in Severe Cardiac and Respiratory Failure (RECOMMEND)","RECOMMEND","PLATFORM INCLUSION CRITERIA:\n\n* Patients receiving ECMO\n* Patients enrolled in the EXCEL Registry - NCT03793257\n\nPLATFORM EXCLUSION CRITERIA:\n\n* Treating clinician regards death as imminent and inevitable\n* Treating clinician determines it is not in the patient's best interests\n\nRBC TRANSFUSION DOMAIN INCLUSION CRITERIA:\n\n• Aged 18 years or older\n\nRBC TRANSFUSION DOMAIN EXCLUSION CRITERIA:\n\n* Contraindication to RBC transfusion (including known patient preference)\n* Limitations of care put in place either through patient wishes or the treating medical teams.\n* Participant has already received ECMO \\>12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated during a surgical intervention in which case the start of ECMO is defined as the arrival time into the initial ICU (post-surgery)\n* The treating physician anticipates that ECMO treatment will cease before the end of tomorrow\n* The treating physician deems the study is not in the patient's best interest\n* The treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds\n* Actively listed for a solid organ transplant and has not yet received one\n* Suspected or confirmed to be pregnant\n* Previous ECMO treatment during the same hospital admission",true,{"count":89,"type":21},600,[91],"PHASE3","The goal of this platform trial is to determine the efficacy, safety and cost-effectiveness of various interventions in patients with acute cardiorespiratory failure requiring extracorporeal membrane oxygenation (ECMO)\n\nThe main question the platform trial aims to address is to determine the effect of a range of interventions on survival, organ support and resource utilisation to day 28 for hospitalised patients receiving ECMO.\n\nResearchers will compare various interventions within multiple platform trial domains to see if the interventions have effects on survival, organ support and resource utilisation for the patient cohort.\n\nParticipants will be enrolled in accordance with the platform trial's domain structure to answer the research questions.",[28,94,95,96,97],"ARDS (Acute Respiratory Distress Syndrome)","Intensive Care Medicine","Cardiac Arrest (CA)","Critical Illness",[99,100,101,102,103,104,105,106,107,108],"ECMO","ICU","Platform Trial","Australia","Cardiac","Respiratory","VA","VV","eCPR","Adaptive","2026-05-11",{"date":111,"type":37},"2026-05-13",{"date":113,"type":37},"2026-03-23",{"date":115,"type":21},"2029-06",{"name":117,"class":44},"Australian and New Zealand Intensive Care Research Centre",3,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":131,"conditions":132,"keywords":133,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":45},"100512961","phase-2-bivalirudin-versus-heparin-in-extracorporeal-membrane-oxygenation-100512961","NCT05959252","BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation","BivaLirudin versUS Heparin in ECMO - A Registry-embedded, Randomised, Open Label, Feasibility Trial Comparing Two Anticoagulation Strategies in Patients on Extracorporeal Membrane Oxygenation (ECMO)","BLUSH","INCLUSION CRITERIA\n\n* Patients receiving ECMO\n* Age: 18 years or older\n* Ability to randomise the patient within 4 hours of ECMO support initiation\n\nEXCLUSION CRITERIA\n\n* Post-cardiotomy ECMO patients\n* Contraindication to heparin or bivalirudin at time of randomisation e.g., active bleeding\n* Heparin induced thrombotic thrombocytopenia syndrome\n* Where the patient is expected to be disconnected from ECMO in the next day after cannulation.\n* Limitations of care put in place either through patient wishes or the treating medical teams\n* Other reason where the treating physician deems the study is not in the patient's best interest\n* Patients who are suspected or confirmed to be pregnant\n* Inherited bleeding or thrombotic disorders, Systemic Lupus Erythematosus patients",{"count":128,"type":21},80,[130],"PHASE2","The goal of this open label randomised clinical trial is to compare Bivalirudin versus Heparin for anticoagulation in patients requiring extracorporeal membrane oxygenation support.\n\nThe main question it aims to answer are include the ability to maintain anticoagulation within defined therapeutic range, bleeding and thrombotic complications and a comparison of the total cost of anticoagulation care.\n\nParticipants will be randomised to either anticoagulation with Bivalirudin or anticoagulation with Unfractionated Heparin.",[28],[99,134,135,136],"Bivalirudin","Heparin","Extracorporeal membrane oxygenation","2026-05-07",{"date":139,"type":37},"2026-05-08",{"date":141,"type":37},"2024-05-01",{"date":143,"type":21},"2026-09-01",{"name":145,"class":146},"Sydney Local Health District","OTHER_GOV",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100473127","platform-of-randomized-adaptive-clinical-trials-in-critical-illness-100473127","NCT05440851","Platform of Randomized Adaptive Clinical Trials in Critical Illness","PRACTICAL","PRACTICAL Platform Inclusion Criteria:\n\n1. Acute hypoxemic respiratory failure meeting all of the following criteria;\n\n   1. New or worsening respiratory symptoms developing within 2 weeks prior to the onset of need for oxygen or respiratory support\n   2. Receiving any of the following types of oxygen or respiratory support for at least 4 hours prior to the time of randomization; supplemental oxygen at 10 L\u002Fmin or higher, high flow nasal oxygen (at any flow rate), invasive ventilator support, extra-corporeal life support (ECLS), or non-invasive ventilator support\n   3. Minimum FiO2 ≥ 0.40 (for venturi mask, high flow nasal cannula, or invasive or non-invasive ventilation) or oxygen flow rate ≥10 L\u002Fmin on face mask for at least 4 hours at the time of evaluation for eligibility unless already on extra-corporeal life support\n2. Age ≥ 18 years\n3. Hypoxemia not primarily attributable to acute heart failure, fluid overload, or pulmonary embolism (PE)\n\nPRACTICAL Platform Exclusion Criteria:\n\n1. Extubation is planned or anticipated on the day of screening\n2. ICU discharged is planned or anticipated on the day of screening\n3. If the patient is moribund and deemed unlikely to survive 24 hours (as determined by the clinical team)\n4. If the patient is being transitioned to a fully palliative philosophy of care\n\nEXPAND-ECLS Domain Inclusion Criteria:\n\n1. Receiving invasive Endotracheal mechanical ventilation for ≤ 72 hours.5 days\n2. Early Moderate-severe hypoxemic respiratory failure with a PaO2\u002FFiO2≤150200 mmHg for at least 6 hours\n\nEXPAND-ECLS Domain Exclusion Criteria:\n\n1. Patients over 70 years of age.\n2. Currently receiving any form of ECLS (e.g., Venovenous, venoarterial, or hybrid configuration).\n3. Chronic hypercapnic respiratory failure defined as PaCO2 \\> 60 mmHg in the outpatient setting.\n4. Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for CPAP\u002FBiPAP used solely for sleep-disordered breathing.\n5. Actual body weight exceeding 1 kg per centimeter of height.\n6. More than 48 hours have passed since meeting inclusion criteria.\n7. Severe hypoxemia with PaO2\u002FFiO2 \\\u003C 80mmHg for \\> 6 hours at time of screening.\n8. Severe hypercapnic respiratory failure with pH \\\u003C 7.25 and PaCO2 \\> 60 mmHg for \\> 6 hours at time of screening.\n9. Expected mechanical ventilation duration \\\u003C 48 hours at time of screening.\n10. Confirmed diffuse alveolar hemorrhage from vasculitis.\n11. Contraindications to limited anticoagulation (e.g., active GI bleeding, bleeding diathesis).\n12. Previous hypersensitivity\u002Fanaphylactic reaction to heparin or heparin-induced thrombocytopenia\n13. Neurologic conditions at risk for or undergoing treatment for intracranial hypertension\n14. Underlying illness with life expectancy \\\u003C 1 year\n15. Pregnancy (due to unknown effects of PaCO2 changes on placental blood flow)\n16. Respiratory failure known or suspected to be caused by COVID-19.\n\nIMV Domain Inclusion Criteria:\n\n1. Intubated patients, not on ECLS, with low normalized respiratory elastance (\\\u003C2.5 cm H2O\u002F(ml\u002Fkg predicted body weight)) at the time of eligibility assessment OR\n2. Intubated patients, not on ECLS, with high normalized respiratory system elastance (≥2.5 cm H2O\u002F(ml\u002Fkg predicted body weight)) at the time of eligibility assessment OR\n3. FOR STUDY SITES PARTICIPATING IN THE LDPVS INTERVENTION: Patient is on ECLS at the time of eligibility assessment. Note: Patients in this state are only eligible for the LPV or LDPVS intervention\n4. FOR STUDY SITES PARTICPATING IN THE EIT INTERVENTION: PaO2\u002FFiO2 (if available) \\\u003C 200 mm Hg at randomization. If PaO2\u002FFiO2 has not been measured, SpO2 = 97% on FiO2 =60%.\n\nIMV Domain Exclusion Criteria:\n\n1. PaO2\u002FFiO2 \\>300 mm Hg or (S\u002FF \\>250, if PaO2\u002FFiO2 has not been measured) at the time of randomization\n2. Chronic hypercapnic respiratory failure defined as PaCO2\\>60mmHg in the outpatient setting\n3. Home mechanical ventilation (non-invasive ventilation or via tracheotomy), not including nocturnal CPAP applied by nasal or face mask or home tracheotomy if not ventilated\n4. Severe hypoxemia with PaO2\u002FFiO2\\\u003C80mmHg for \\>6 consecutive hours at the time of randomization\n5. Severe hypercapnic respiratory failure with pH\\\u003C7.25 and PaCO2\\>60mmHg for \\>6 consecutive hours at the time of randomization\n6. Anticipated duration of mechanical ventilation is \\\u003C48 hours from the time of screening\n7. Duration of mechanical ventilation during current ICU admission is \\>72 hours\n8. Previously diagnosed neuromuscular disorder\n9. Current diagnosis of severe acute brain injury (e.g. ischemic or hemorrhagic stroke, traumatic brain injury) with Glasgow Coma Scale ≤ 8\n10. Baseline weight prior to or at hospital admission less than 35 kilograms\n11. Receiving extracorporeal life support without continuous invasive mechanical ventilatory support\n\nCORT-E2 Domain Early Cohort Inclusion Criteria\n\n1. Within 72 hours of admission to an ICU\n2. New unilateral or bilateral airspace disease\n\nCORT-E2 Domain Early Domain Exclusion Criteria\n\n1. Receiving only low flow oxygen therapy less than or equal to 15L\u002Fmin\n2. Corticosteroid use during the 14 days prior to screening\n3. Existing indication for corticosteroids\n4. High suspicion for\u002For confirmed COVID infection\n5. Acute traumatic brain injury during the index hospital admission\n6. Allergy to dexamethasone\n\nCORT-E2 Domain Extended Cohort Inclusion Criteria\n\n1. Are admitted to an ICU\n2. Have already received 10 days of corticosteroid specifically for acute respiratory failure, this will include patients: (a) randomized to corticosteroid arm in Early Cohort, (b) patients with COVID receiving corticosteroids as standard of care , (c) and others who have received corticosteroids for AHRF\n3. Ongoing AHRF requiring HFNC, NIV (continuous positive airway pressure \\[CPAP\\] or bilevel) or invasive ventilation\n\nCORT-E2 Domain Extended Cohort Exclusion Criteria\n\n1. An alternate indication for ongoing corticosteroids\n2. Acute traumatic brain injury this hospital admission\n\nFLUDRO Domain Inclusion Criteria 1. Within 72 hours of admission to an ICU\n\nFLUDRO Domain Exclusion Criteria\n\n1. Known hypersensitivity to fludrocortisone\n2. An inability to receive fludrocortisone due to lack of enteral access\n3. An indication to prescribe fludrocortisone for a reason that is unrelated to a current episode of pneumonia or acute respiratory failure, such as Addison's disease\n4. Belief of the treating clinical team that study participation would not be in the best interest of the patient\n\nFAST-3 Domain Inclusion Criteria (must meet all 3 of the following)\n\n1. Patient is in a PRACTICAL eligible platform state and requires advanced respiratory support (ARS) defined as one of the following:\n\n   a. Invasive mechanical ventilation with FiO2 \\> 40% b. Non-Invasive Ventilation (\\> 4 hours consecutively with FiO2 \\> 40%) defined as: i. CPAP or BiPAP (any settings or interface) ii. HFNC (flow \\> 40 liter per minute)\n2. PaO2\u002FFiO2 \\\u003C 300 mm Hg or SpO2\u002FFiO2 \\\u003C 315 (if PaO2\u002FFiO2 unavailable due to lack of arterial blood gas at the time of screening). For SpO2\u002FFiO2, criteria are SpO2 ≤ 97% on FiO2 ≥ 40% on both of the 2 hours immediately preceding eligibility assessment. If an arterial blood gas can be obtained, then a PaO2\u002FFiO2 ratio is preferable.\n3. Patient commenced advanced respiratory support \\\u003C 48 hours prior to randomization.\n\nFAST-3 Domain Exclusion Criteria\n\n1. Patient commenced advanced respiratory support \\> 48 hours to time of randomization.\n2. Known history of severe chronic pulmonary disease e.g., pre-infection requirement for home oxygen therapy or presence of chronic hypercapnia (PaCO2 \\> 60 mmHg); mild - moderate disease is still eligible in the absence of chronic hypercapnia or need for chronic oxygen therapy.\n3. Currently enrolled in another trial studying investigational anti-inflammatory therapy, excluding established treatments used in clinical practice such as corticosteroids.\n4. Known allergy to furosemide or sulfonamide drugs. If the patient is allergic to sulfonamide drugs but has received in the past or is currently receiving furosemide without incident, they can be enrolled since cross-reactivity between furosemide and sulfonamide agents is rare.\n\nESCAPE Domain Inclusion Criteria\n\n1. Patients with severe AHRF who have an underlying immunocompromised condition\n2. Within 48 hours of fulfilling the AHRF inclusion criteria as well as PaO2\u002FFiO2 \\\u003C300 or a SaO2\u002FFiO2 \\\u003C 315 on non-invasive respiratory support (venturi mask, non-invasive ventilation or high flow nasal oxygen as per the FiO2 requirements above) or invasive ventilation.\n\nPatients may be enrolled from the wards or ICU.\n\nImmunocompromised patients include:\n\n1. Any patients requiring long term (\\>30 days) corticosteroids (\\>20 mg\u002Fday),\n2. Any patients receiving non-corticosteroid immunosuppressive medications within the prior 3 months,\n3. Acquired or inherited immunodeficiency syndrome,\n4. Recipients of solid organ transplant,\n5. Active hematologic malignancy (diagnosis or receiving treatment within prior 6 months),\n6. Active solid tumor (diagnosis or receiving treatment within the prior 6 months) or\n7. Any patients who have undergone allogeneic or autologous hematopoietic cell transplant in the prior 6 months (HCT).\n\n   ESCAPE Domain Exclusion Criteria\n   1. Patients whom are deemed palliative.\n\n   WAVEFORM Domain Inclusion Criteria\n\n   1\\. Patient is intubated at the time of eligibility assessment.\n\n   WAVEFORM Domain Exclusion Criteria\n   1. PaO2\u002FFiO2 \\>300 mm Hg or (S\u002FF \\>250, if PaO2\u002FFiO2 has not been measured) at the time of eligibility assessment.\n   2. Duration of mechanical ventilation during current ICU admission is ≥72 hours.\n   3. Receiving ECLS without continuous invasive mechanical ventilatory support.\n\n   IMV-ECLS Domain Inclusion Criteria\n\n   1\\. Patients with AHRF (as defined in platform inclusion criteria #1 above) who have been consented for cannulation for VV-ECLS or who have been initiated on VV-ECLS within 6 hours at the time of randomization\n\n   IMV-ECLS Domain Exclusion Criteria 1. Patients receiving ECLS for the primary intention of extracorporeal CO2 removal 2. Patients expected to be liberated from ECLS within \\\u003C24 hours 3. History of recent pneumothorax or pneumomediastinum (\\\u003C3 months at the time of eligibility assessment\u002Frandomization) 4. Patients receiving ECLS for the primary intention of bridge to lung transplantation (at the time of eligibility assessment\u002Frandomization)\n\n   IMPROV Domain Inclusion Criteria\n   1. Patients receiving invasive mechanical ventilation for AHRF as defined by the PRACTICAL platform trial criteria above.\n   2. Within 7 calendar days of intubation\n\n   IMPROV Domain Exclusion Criteria\n   1. Patient is expected to be liberated from mechanical ventilation within 24 hours\n   2. Known or suspected chronic hypercapnic respiratory failure defined as PaCO2\\>60mmHg in the outpatient setting\n   3. Home mechanical ventilation (non-invasive ventilation or via tracheotomy), not including nocturnal CPAP applied by nasal or face mask or home tracheotomy if not ventilated\n   4. Known pneumothorax or pneumomediastinum without chest tube placement sustained during current ICU admission\\* (re-confirm immediately prior to randomization)\n   5. Patient is admitted primarily for acute brain injury (stroke, traumatic brain injury, etc.)\n   6. Previously diagnosed chronic neuromuscular disorder\n   7. Patient has an implantable cardiac defibrillator or pacemaker\n   8. Planned to be transferred to another hospital before ICU discharge\n   9. Already receiving a regimen of inspiratory muscle training using external resistive device or diaphragm neurostimulation",{"count":155,"type":21},6250,[24],"PRACTICAL is a randomized multifactorial adaptive platform trial for acute hypoxemic respiratory failure (AHRF). This platform trial will evaluate novel interventions for patients with AHRF across a range of severity states (i.e., not intubated, intubated with lower or higher respiratory system elastance, requiring extracorporeal life support) and across a range of investigational phases (i.e., preliminary mechanistic trials, full-scale clinical trials). AHRF is a common and life-threatening clinical syndrome affecting millions globally every year. Patients with AHRF are at high risk of death and long-term morbidity. Patients who require invasive mechanical ventilation are at risk of ventilator-induced lung injury and ventilator-induced diaphragm dysfunction. New treatments and treatment strategies are needed to improve outcomes for these very ill patients.\n\nUtilizing advances in Bayesian adaptive trial design, the platform will facilitate efficient yet rigorous testing of new treatments for AHRF, with a particular focus on mechanical ventilation strategies and extracorporeal life support techniques as well as pharmacological agents and new medical devices.\n\nThe platform is designed to enable evaluation of novel interventions at a variety of stages of investigation, including pilot and feasibility trials, trials focused on mechanistic surrogate endpoints for preliminary clinical evaluation, and full-scale clinical trials assessing the impact of interventions on patient-centered outcomes.\n\nA domain is defined as a set of interventions that are intended to act on specific mechanisms of injury using different variations of a common therapeutic strategy. A domain may also be a non-interventional study that addresses observational research questions by collecting specific data or outcomes that are not collected as part of other domains. Domains are intended to function independently of each other, allowing independent evaluation of multiple therapies and mechanistic pathways within the same patient.\n\nOnce feasibility is established, Bayesian adaptive statistical modelling will be used to evaluate treatment efficacy at regular interim adaptive analyses of the pre-specified outcomes for each intervention in each domain. These adaptive analyses will compute the posterior probabilities of superiority, futility, inferiority, or equivalence for pre-specified comparisons within domains. Each of these potential conclusions will be pre-defined prior to commencing the intervention trial. Decisions about trial results (e.g., concluding superiority or equivalence) will be based on pre-specified threshold values for posterior probability. The primary outcome of interest, the definitions for superiority, futility, etc. (i.e., the magnitude of treatment effect) and the threshold values of posterior probability required to reach conclusions for superiority, futility etc., will vary from intervention to intervention depending on the phase of investigation and the nature of the intervention being evaluated. All of these parameters will be pre-specified as part of the statistical design for each intervention trial.\n\nIn general, domains will be designed to evaluate treatment effect within four discrete clinical states: non-intubated patients, intubated patients with low respiratory system elastance (\\\u003C2.5 cm H2O\u002F(mL\u002Fkg)), intubated patients with high respiratory system elastance (≥2.5 cm H2O\u002F(mL\u002Fkg)), and patients requiring extracorporeal life support. Where appropriate, the model will specify dynamic borrowing between states to maximize statistical information available for trial conclusions. In this perpetual trial design, different interventions may be added or dropped over time.\n\nWhere possible, the platform will be embedded within existing data collection repositories to enable greater efficiency in outcome ascertainment. Standardized systems for acquiring both physiological and biological measurements are embedded in the platform, to be acquired at sites with appropriate training, expertise, and facilities to collect those measurements.",[159,28,160],"Respiratory Insufficiency","Mechanical Ventilation Pressure High","2026-05-01",{"date":137,"type":37},{"date":164,"type":37},"2023-04-30",{"date":166,"type":21},"2027-03-31",{"name":168,"class":44},"University Health Network, Toronto",89,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":179,"conditions":180,"keywords":183,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":196},"100604988","safety-and-performance-of-the-novalung-ultimate-kit-and-xenios-20-during-stationary-use-in-hospital-and-ground-based-transport-of-patients-on-extracorporeal-life-support-ecls-100604988","NCT07156669","Safety and Performance of the Novalung Ultimate Kit and Xenios 2.0 During Stationary Use in Hospital and Ground-based Transport of Patients on Extracorporeal Life Support (ECLS)","Transport+","Inclusion Criteria:\n\n* Adult patients receiving an ECMO treatment with the Novalung ultimate kit in combination with the Xenios 2.0 (and the MultiSupport Ground during inter- and intra-hospital transport, if applicable) according to the intended use\n* Informed consent signed and dated by the attending physician; and\n\n  1. If patient is able to give consent: by the study patient\n  2. If patient is unable to give consent: by the legal representative or\n  3. If an emergency situation is determined: by a consultant physician\n\nExclusion Criteria:\n\n* Participation in any interventional clinical study that could impact the results of this prospective, observational PMCF study\n* Previous participation in the same study\n* ECMO cannulation outside the referring or trial site hospital",{"count":178,"type":21},20,"This prospective observational study will evaluate the safety and performance of the Novalung ultimate kit in combination with the Xenios 2.0 and the MultiSupport Ground during stationary use in hospital and ground-based transport of patients treated on extracorporeal membrane oxygenation (ECMO). The primary objective is to assess whether the use of the medical devices improves and maintains the gas exchange (blood oxygenation) in these patients. Medical Devices will be used according to their intended purpose and local standards\u002F requirements.",[181,28,182],"Cardio-Respiratory Failure","Acute Lung Injury",[184,185],"Extracorporeal Life Support","Extracorporeal Membrane Oxygenation","2026-04-08",{"date":188,"type":37},"2026-04-13",{"date":190,"type":21},"2026-04",{"date":192,"type":21},"2027-07",{"name":194,"class":195},"Xenios AG","INDUSTRY",2,{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":221},"100578672","phase-3-continuous-positive-airway-pressure-on-venovenous-extracorporeal-membrane-oxygenation-for-acute-respiratory-distress-syndrome-100578672","NCT06814340","\"Continuous Positive Airway Pressure on Venovenous extracorporeaL Membrane Oxygenation for Acute respIratory Distress syndrOme\"","\"Continuous Positive Airway Pressure on Venovenous extracorporeaL Membrane Oxygenation for Acute respIratory Distress syndrOme\" - CALMDOWN","CALMDOWN","Inclusion Criteria:\n\n1. Severe acute respiratory distress syndrome refractory to conventional therapy placed on VV-ECMO support in the 48 hours (maximum tolerance : +2h) preceding inclusion.\n2. Obtain informed consent from a close relative or surrogate. According to the specifications of emergency inclusion, randomization without the close relative\u002Fsurrogate consent could be performed if the patient is unable to give his\u002Fher consent and when the close relative\u002Fsurrogate\u002Ffamily member are absent. Close relative\u002Fsurrogate\u002Ffamily member consent will be asked as soon as possible after randomization. The patient will be asked as soon as possible to give his\u002Fher consent for the continuation of the trial when his\u002Fher condition will allow.\n3. French Social security registration (except AME)\n\nExclusion Criteria:\n\n1. Age \\\u003C 18\n2. Pregnancy or breastfeeding\n3. Initiation of VV-ECMO \\> 48 h (maximum tolerance : +2h)\n4. Cardiac arrest with cumulated no flow time \\>10 minutes before ECMO (within 48 hours prior to inclusion)\n5. Irreversible neurological pathology\n6. End-stage chronic lung disease\n7. Contraindications for high PEEP level: untreated pneumothorax, barotrauma\n8. Irreversible ARDS with no hope for lung function recovery\n9. Patient moribund on the day of randomization, SAPS II \\>90\n10. Liver cirrhosis (Child B or C)\n11. Lung transplantation\n12. Burns on more than 20 % of the body surface\n13. Participation in another interventional study with a similar primary endpoint (mortality, lung transplantation, or duration of ECMO) or being in the exclusion period at the end of a previous study\n14. Individuals under guardianship, or permanently legally incompetent adults",{"count":206,"type":21},280,[91],"The CALMDOWN trial is a prospective, open-label, multicenter, comparative, controlled trial randomizing patients who received near apneic ventilation vs usual care on ECMO (ultra-protective lung ventilation).\n\nThe study goal is to investigate the benefit of early apneic ventilation in the most severe forms of acute respiratory distress syndrome (ARDS) rescued by ECMO.\n\nIndeed, our hypothesis is that that early (near) apneic ventilation on venovenous ECMO for severe ARDS can enhance ventilator injury prevention and therefore reduce ECMO duration and mortality at Day 60.",[210,28],"Acute Respiratory Distress Syndrome",[99,212,213],"ARDS","CPAP",{"date":188,"type":37},{"date":216,"type":37},"2025-05-06",{"date":218,"type":21},"2030-05-06",{"name":220,"class":44},"Assistance Publique - Hôpitaux de Paris",11,{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":45},"100537263","use-of-bivalirudin-for-anticoagulation-in-patients-with-extracorporeal-membrane-oxygenation-100537263","NCT06275555","Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation","Efficacy and Safety of Bivalirudin Versus Heparin in Anticoagulant Therapy of ECMO: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Accept VA-ECMO or VV-ECMO\n3. the ECMO team believes that systemic anticoagulation is necessary and that APTT should be maintained at 40-60s.\n4. sign the informed consent form\n\nExclusion Criteria:\n\n1. previous history of allergy to heparin or bivalirudin\n2. previous diagnosis of heparin-induced thrombocytopenia.\n3. the pre-random ECMO assistance time is more than 48 hours.\n4. pregnant female\n5. have participated in this study before.\n6. the researchers believe that there are other factors that are not suitable to participate in this study.",{"count":230,"type":21},154,[24],"The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.",[28],"2026-04-02",{"date":236,"type":37},"2026-04-06",{"date":238,"type":37},"2024-06-03",{"date":240,"type":21},"2027-03-01",{"name":242,"class":44},"Xiaotong Hou",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":250,"maxAge":54,"enrollmentInfo":251,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":253,"conditions":254,"keywords":256,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":45},"100358513","study-on-the-efficacy-and-timing-of-ecmo-therapy-in-children-with-refractory-septic-shock-100358513","NCT03948048","Study on the Efficacy and Timing of ECMO Therapy in Children With Refractory Septic Shock","Study on the Efficacy and Timing of Extracorporeal Membrane Oxygenation (ECMO) Therapy in Children With Refractory Septic","Inclusion Criteria:\n\n• Children with septic shock and refractory septic shock admitted to the PICU of all the study centers\n\nExclusion Criteria:\n\n* Fatal chromosomal abnormalities (e.g., trisomy 13 or 18)\n* Uncontrolled bleeding\n* Irreversible brain damage\n* After allogeneic bone marrow transplantation\n* Weight less than 2.5kg or severe malnutrition","29 Days",{"count":252,"type":21},60,"Severe sepsis and septic shock remain the leading causes of child mortality worldwide. Sepsis is a complex process that ultimately leads to circulation disorders, organ perfusion abnormalities, capillary leakage, tissue hypoxia, and organ failure. The difficulty of clinical treatment is microcirculation and mitochondrial dysfunction in septic shock. Once shock enters the stage of microcirculation failure, conventional treatment is ineffective. ECMO can effectively support the circulatory system and provide good oxygen delivery, but there are many controversies in clinical treatment. 1) whether ECMO can effectively improve the clinical prognosis of children with septic shock; 2) appropriate timing for ECMO intervention; 3) which key clinical factors affect the effect of ECMO treatment. This study intends to adopt a multi-center, prospective, non-randomized controlled trial design, and the main research hypothesis is whether ECMO treatment can improve the success of discharge survival of children with septic shock.",[255,28],"Septic Shock",[257,258,99,259],"septic shock","children","timing","2026-03-13",{"date":262,"type":37},"2026-03-16",{"date":264,"type":37},"2020-08-01",{"date":266,"type":21},"2026-12-31",{"name":268,"class":44},"Children's Hospital of Fudan University",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":22,"phases":278,"briefSummary":279,"conditions":280,"keywords":281,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":45},"100383511","phase-2-anticoagulation-free-vv-ecmo-for-acute-respiratory-failure-100383511","NCT04273607","Anticoagulation-free VV ECMO for Acute Respiratory Failure","Anticoagulation-free VV ECMO for Acute Respiratory Failure: A Pilot Safety and Feasibility Randomized Clinical Trial","A-FREE ECMO","Inclusion Criteria:\n\n* Adult patient with ARDS on VV-ECMO\n\nExclusion Criteria:\n\n* Contraindication to anticoagulation with UFH (known heparin-induced thrombocytopenia, active hemorrhage, any surgery precluding the use of anticoagulation),\n* Indication for therapeutic anticoagulation (pulmonary embolism or deep vein thrombosis, chronic anticoagulation therapy before ECMO insertion)\n* Low-flow (\\\u003C2 liters\u002Fmin) VV-ECMO (ECCO2R)",{"count":56,"type":21},[130,91],"Currently international experts recommend therapeutic anticoagulation for veno-venous extracorporeal membrane oxygenation (VV-ECMO). Reports and case series suggest that the absence of therapeutic anticoagulation is safe for VV-ECMO. No randomized control trials have assessed this. The aim of this pilot study is to assess safety and feasibility of an \"anticoagulation-free strategy\" for veno-venous ECMO (VV-ECMO) in Acute respiratory distress syndrome (ARDS).",[28],[136,282,62,60],"Anticoagulation","2026-01-14",{"date":285,"type":37},"2026-01-16",{"date":287,"type":37},"2022-09-01",{"date":289,"type":21},"2027-01-30",{"name":291,"class":44},"Damian Ratano",{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":18,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":45},"100274401","transplantation-of-autologously-derived-mitochondria-following-ischemia-100274401","NCT02851758","Transplantation of Autologously Derived Mitochondria Following Ischemia","Transplantation of Autologously Derived Mitochondria for Protection Against Ischemia-reperfusion Injury Following Ischemia in Subjects on ECMO Support","Inclusion Criteria:\n\n* Pediatric cardiology patients under the age of 18 on ECMO\n* concerns for ischemic injury on the Cardiac Intensive Care Unit\n\nExclusion Criteria:\n\n* Known mitochondria disorders",{"count":300,"type":21},16,[24],"The investigators propose a robust therapeutic intervention to ameliorate myocardial ischemia\u002F reperfusion injury and significantly decrease morbidity and mortality in patients requiring extracorporeal membrane oxygenation (ECMO), by direct injection of autogeneic mitochondria into the ischemic myocardium.",[28],"2025-12-30",{"date":306,"type":37},"2026-01-05",{"date":308,"type":37},"2017-08-02",{"date":310,"type":21},"2027-06",{"name":312,"class":44},"Boston Children's Hospital",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":329,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":45},"100503089","continuous-compartment-pressure-monitoring-for-compartment-syndrome-in-va-ecmo-patients-100503089","NCT05830721","Continuous Compartment Pressure Monitoring for Compartment Syndrome in VA-ECMO Patients","Continuous Compartment Pressure Monitoring for Compartment Syndrome in Venoarterial-Extracorporeal Membrane Oxygenation Patients - A Preliminary Feasibility Study","VA-ECMO","Inclusion Criteria:\n\n* Adults ≥18 years of age\n* Peripheral Venoarterial-Extracorporeal membrane oxygenation\n* Sedated\n\nExclusion Criteria:\n\n* Any limb ischemia diagnosis prior to ECMO cannulation\n* Any severe extremity trauma that precludes insertion of device\n* Very poor prognosis (survival \\>72 hours is unlikely), which also includes severe coagulopathy. Severely coagulopathic patients are at risk for severe hemorrhage and thus may not survive fasciotomy.",{"count":322,"type":21},6,[24],"Acute compartment syndrome (ACS) is a surgical emergency that can develop in patients on extracorporeal membrane oxygenation (ECMO). ACS is a type of limb ischemia, which means that the limb, such as the arm or leg, loses blood flow. Patients on ECMO can develop this condition for many reasons, but most commonly from the ECMO procedure itself. This most commonly involves the leg. Key symptoms of ACS include severe pain, loss of pulses, loss of feeling, and inability to move the limb. However, because patients on ECMO are often sedated, ACS is difficult to diagnose as patients can not report symptoms. As a result, the only available tool for diagnosing ACS may be measurement of pressures in the limb. This is normally done with a needle-device, which is inserted into the leg for a single measurement. However, a recently developed device, called the MY01 Continuous Compartment Pressure Monitor, allows for continuous pressure readings instead of a single measurement. Multiple measurements may allow for much greater accuracy in diagnosing ACS, which may result in faster time to surgery and potentially save more limbs than single measurements. This device may also be less invasive than an older method of continuous pressure measuring, which uses a needle and tubing that is 14-gauge in size. Therefore, this study aims to compare 3 different types of methods for diagnosing ACS in patients on ECMO, which are 1) Standard of Care, 2) Standard of Care and MY01, and 3)Standard of Care and 14-gauge slit catheter.",[326,28,327,328],"Compartment Syndrome of Leg","Limb Ischemia","Limb Ischemia, Critical",[330,331,332,99],"Compartment Syndrome","Venoarterial Extracorporeal Membrane Oxygenation","Compartment Pressure Measurement","2025-12-23",{"date":335,"type":37},"2025-12-24",{"date":337,"type":37},"2024-01-02",{"date":339,"type":21},"2027-12",{"name":341,"class":44},"Johns Hopkins University",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":349,"enrollmentInfo":350,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":351,"conditions":352,"keywords":355,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":196},"100573765","evaluating-the-safety-and-performance-of-the-minilung-petite-kit-in-neonatal-and-pediatric-patients-with-acute-respiratory-and-cardiac-failure-100573765","NCT06750536","Evaluating the Safety and Performance of the MiniLung Petite Kit in Neonatal and Pediatric Patients With Acute Respiratory and Cardiac Failure","PETIT","Inclusion criteria\n\n* Informed consent signed and dated by parents or legal representative and investigator\u002Fauthorized physician\n* Patients ≥2- ≤8 kg bodyweight to be treated with the MiniLung petite kit\n* Acute severe respiratory and\u002For cardiopulmonary failure with an ECMO indication\n\nExclusion criteria:\n\n* Participation in an interventional clinical study during the preceding 30 days that could interfere with the ECLS therapy\n* Previous participation in the same study\n* Prematurity (\\\u003C34 weeks gestational age)\n* Hypersensitivity to heparin or known history of heparin induced thrombocytopenia (HIT)\n* Impossibility of systemic anticoagulation","8 Months",{"count":178,"type":21},"This prospective observational study will evaluate the safety and performance of the MiniLung petite kit in neonatal and pediatric patients with acute respiratory and cardiac failure.\n\nThe main question it aims to answer is (study hypotheses):\n\nVeno-venous (VV) and veno-arterial (VA) Extracorporeal Membrane Oxygenation (ECMO) using the MiniLung petite kit is safe and improves gas exchange (oxygenation and CO2 removal) and hemodynamic stabilization in neonatal and pediatric patients with severe acute respiratory and\u002For cardiopulmonary failure within 24 hours compared to the treatment before VV or VA ECMO initiation and maintain a life-sustaining condition.",[28,353,354,182],"Neonatal Aspiration Pneumonia","Acute Respiratory Failure",[185,356,357],"Neonatal and pediatric patients","MiniLung petite kit","2025-12-18",{"date":335,"type":37},{"date":361,"type":37},"2025-10-12",{"date":363,"type":21},"2026-12",{"name":194,"class":195},{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":22,"phases":373,"briefSummary":374,"conditions":375,"keywords":376,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":385,"locationsCount":45},"100537298","use-of-nafamostat-mesilate-for-anticoagulation-in-patients-with-ecmo-100537298","NCT06276010","Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO","Use of Nafamostat Mesilate for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation After Cardiac Surgery: Efficacy and Safety","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. VA-ECMO or VV-ECMO was accepted after cardiac surgery.\n3. The ECMO treatment team believes that systemic anticoagulation is needed\n4. Sign the informed consent form\n\nExclusion Criteria:\n\n1. The researchers believe that there are other causes of active bleeding that are not suitable to participate in this study.\n2. Long-term use of anticoagulants before establishment of ECMO\n3. Antiplatelet drugs were used before the establishment of ECMO\n4. Severe liver insufficiency\n5. Connective tissue disease\n6. There is a history of allergy to heparin or nemolastat mesylate.\n7. Pregnant\n8. Previous diagnosis of heparin-induced thrombocytopenia\n9. Expect to die within 48 hours\n10. ECPR",{"count":128,"type":21},[24],"The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.",[28],[377,378],"anticoagulation","nafamostat mesilate","2025-09-22",{"date":381,"type":37},"2025-09-25",{"date":383,"type":37},"2024-07-01",{"date":266,"type":21},{"name":242,"class":44},{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":396,"conditions":397,"keywords":399,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":45},"100523425","dic-markers-and-thrombin-generation-parameters-in-patients-on-ecmo-support-a-pilot-study-100523425","NCT06095518","DIC Markers and Thrombin Generation Parameters in Patients on ECMO Support: a Pilot Study","DIC-ECMO","Inclusion Criteria:\n\n* Age ≧ 18; AND\n* Admitted to the mixed medical-surgical intensive care units of Queen Mary Hospital or Tuen Mun Hospital in Hong Kong; AND\n* Require either veno-arterial (VA) or veno-venous (VV) extracorporeal membrane oxygenation (ECMO) support.\n\nExclusion Criteria:\n\n* Patients who are on central VA-ECMO support; OR\n* Patients with missing clinical data; OR\n* Patients with pre-existing thromboembolism requiring long term anticoagulation prior to ECMO cannulation; OR\n* Post-operative admissions","80 Years",{"count":395,"type":21},50,"To study the correlation between novel DIC markers and thrombin generation parameters with thrombotic and hemorrhagic complications of patients on ECMO support.",[398,28],"Extracorporeal Circulation; Complications",[99,62,400],"Haemorrhage","2025-07-21",{"date":403,"type":37},"2025-07-24",{"date":405,"type":37},"2023-05-30",{"date":407,"type":21},"2025-12-31",{"name":409,"class":44},"Queen Mary Hospital, Hong Kong",{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":418,"conditions":419,"keywords":420,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":45},"100451855","eurosets-ecmo-study-in-clinical-extracorporeal-life-support-applications-100451855","NCT05163925","EUROSETS ECMO Study in Clinical Extracorporeal Life Support Applications","A Prospective Single Center Study to Evaluate Safety and Efficacy of the EUROSETS Extracorporeal Membrane Oxygenation ECMOLIFE SYSTEM in Clinical Extracorporeal Life Support Applications EUROSETS ECMO STUDY","Inclusion Criteria:\n\n* Patients ≥18 years\n* VA-ECLS application using the EUROSETS ECMOLIFE SYSTEM (e.g. cardiogenic shock, post cardiotomy low cardiac output syndrome, cardiac arrest, high risk percutaneous coronary intervention, eCPR)\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years\n* Pregnant and breastfeeding women",{"count":20,"type":21},"This is a prospective single-center study designed for evaluation of safety and performance of the Conformitè Europëenne (CE)-marked EUROSETS ECMOLIFE SYSTEM, composed by: ECMOLIFE console, ECMO TUBING SET, ECMO OXYGENATOR and ECMOLIFE CENTRIFUGAL PUMP, HEATER COOLER (called ECMOLIFE HC) in all clinical ECLS applications (e.g. post-cardiotomy ECLS as well as application for cardiogenic shock after myocardial infarction or resulting from other etiologies, as well as ECLS application in patients under cardiopulmonary resuscitation (eCPR) and protected PCI) in 30 consecutive patients.\n\nAll demographic and perioperative variables (ECMOLIFE SYSTEM -related and unrelated ECLS complications, performances of the ECMOLIFE SYSTEM) will be analyzed. Surgical techniques will be recorded. Follow-up information on survival and any adverse cardiac and cerebrovascular events will be gathered routinely by outpatient clinic and telephone calls until 30 days after ECLS initiation or hospital discharge.",[28],[421],"Extracorporeal Life Support Applications","2025-07-01",{"date":424,"type":37},"2025-07-02",{"date":426,"type":37},"2022-01-10",{"date":428,"type":21},"2025-07",{"name":430,"class":195},"Eurosets S.r.l.",{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":87,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":22,"phases":440,"briefSummary":441,"conditions":442,"keywords":447,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":465,"locationsCount":196},"100501810","red-blood-cell-transfusion-in-ecmo---a-feasibility-trial-100501810","NCT05814094","Red Blood Cell Transfusion in ECMO - A Feasibility Trial","ROSETTA","Inclusion Criteria:\n\n* Patients receiving ECMO\n* Age: 18 years or older\n\nExclusion Criteria:\n\n* Contraindication to RBC transfusion (including known patient preference)\n* Limitations of care put in place either through patient wishes or the treating medical teams\n* ECMO treatment for more than 12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated during a surgical intervention in which case the start is defined as the arrival time into the initial ICU.\n* The treating physician anticipates that ECMO treatment will cease before the end of tomorrow\n* Where the treating physician deems the study is not in the patient's best interest\n* Where the treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds\n* Patients actively listed for a solid organ transplant\n* Patients who are suspected or confirmed to be pregnant\n* Previous ECMO treatment during the same hospital admission",{"count":439,"type":21},120,[24],"Extracorporeal Membrane Oxygenation (ECMO) is an invasive and resource intense treatment used to support critically ill patients who have suffered severe cardiac arrest, cardiac failure or respiratory failure (including severe cases of COVID-19). ECMO acts as a mechanical circulatory support temporarily replacing the function of the heart or lungs by oxygenating blood and removing carbon dioxide, allowing time for these organs to recover. Many critically ill patients, including those on ECMO, have an increased risk of bleeding and reduced production\u002Fincreased destruction of red blood cells (RBCs). This can lead to anaemia (haemoglobin levels \\\u003C120 g\u002Fl), a condition where the body lacks enough healthy RBCs to carry enough oxygen to the body's tissues. Therefore, patients on ECMO frequently require RBC transfusion, with clinicians having to decide if administering an RBC transfusion (with its associated risks) is higher than tolerating complications of anaemia.\n\nROSETTA is a feasibility study that aims to determine the safety and feasibility of randomizing patients on ECMO to a restrictive RBC transfusion strategy (maintain Hb concentration above 70g\u002FL) or to a more liberal transfusion strategy (maintain Hb concentration above 90g\u002FL). Feasibility is defined as the ability to achieve a mean separation of at least 10g\u002FL between the average lowest daily haemoglobin values in the two study groups.",[443,28,444,445,446],"Blood Loss Anemia","Disability Physical","Cognitive Ability, General","Functional Status",[448,449,99,450,451,452,102,453,100,454,455,456,457,458],"Hb","RBC transfusion","feasibility","safety","blood transfusion","blood products","critical care","intensive care","bleeding","transfusion","Hb values","2025-05-27",{"date":461,"type":37},"2025-05-31",{"date":463,"type":37},"2023-09-20",{"date":304,"type":21},{"name":117,"class":44},{"id":467,"slug":468,"hasResults":11,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":22,"phases":475,"briefSummary":476,"conditions":477,"keywords":480,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":494,"locationsCount":45},"100577003","phase-2-cangrelor-on-top-of-anticoagulation-in-patients-with-myocardial-infarction-related-cardiogenic-shockcardiac-arrest-receiving-va-ecmo-100577003","NCT06792643","Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock\u002FCardiac Arrest receiVIng VA-ECMO","Efficacy and Safety of Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction Related Cardiogenic Shock\u002FCardiac Arrest receiVIng VAECMO Support - a Phase 2, Single Arm, Single Center Trial","SURVIVE","Inclusion Criteria:\n\n* Male or female patients aged ≥18 years;\n* ACS-related CS\u002FCA patients undergoing PCI (either with or without stent implantation) and needing VA-ECMO support;\n* Patients who received pre-hospital aspirin intravenous loading dose or patients naïve to any anti-thrombotic agent;\n* Written informed consent\n\nExclusion Criteria:\n\n* Overt uncontrollable bleeding;\n* Suspected intra-cranial haemorrhage;\n* Patients who received any dose of any oral P2Y12-inhibitors;\n* Patients with known history of stroke or Transient Ischaemic Attack (TIA);\n* Patients with known hypersensitivity to the active substance (cangrelor) or to any of its excipients;\n* Pregnancy.",{"count":395,"type":21},[130],"The SURVIVE trial aims to test whether using an anti-thrombotic regimen involving cangrelor can reduce bleeding risk while maintaining effective antithrombotic effects in patients on VA-ECMO due to cardiogenic shock (CS)\u002F cardiac arrest (CA) who undergo percutaneous coronary intervention (PCI). The investigators plan to achieve this by starting cangrelor on top of systemic anticoagulation with bivalirudin at a low dose, regularly monitoring platelet function, and adjusting the dose based on the results of platelet function assay (Multiplate®) to guarantee effective platelet P2Y12 pathway inhibition to achieve optimal platelet inhibition. Platelet function assays will be performed at various time points throughout the treatment timeframe. Cangrelor will then be stopped at the end of VA-ECMO support, and patients will be transitioned to oral P2Y12- inhibitors as per clinical guidelines.",[478,28,479],"Cardiogenic Shock","Platelet Dysfunction",[481,482,478,483,99,484,485,486,487,185],"Cangrelor","ACS","PCI","VA-EMO","Acute coronary syndrome","P2Y12","Anti-thrombotic therapy","2025-01-21",{"date":490,"type":37},"2025-01-27",{"date":492,"type":37},"2024-04-01",{"date":407,"type":21},{"name":495,"class":44},"IRCCS San Raffaele",{"id":497,"slug":498,"hasResults":11,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":11,"sex":16,"minAge":504,"maxAge":393,"enrollmentInfo":505,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":507,"conditions":508,"keywords":511,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":519,"leadSponsor":521,"locationsCount":45},"100574955","ecmo-left-ventricle-unloading-strategy-100574955","NCT06766006","ECMO LEft Ventricle UNloading Strategy","A Multicentric Left Ventricular Venting Strategy Comparison in Patients Receiving Venoarterial Extracorporeal Life Support","ECMOLENS","Inclusion Criteria:\n\n* All patients undergoing VA ECLS will be enrolled.\n\nExclusion Criteria:\n\n* Patients without VA ECMO will not be considered","1 Day",{"count":506,"type":21},500,"The present study is an International multicentric prospective observational cohort study. This will be an international research campaign to prospectively collect and analyze clinical data of all VA ECLS patients admitted to participating ICUs with a focus on LV venting modalities. The aims of the study are:\n\n* To investigate the meaning of LV overload during veno-arterial (VA) extracorporeal life support;\n* To extensively describe the left ventricular (LV) unloading strategy during VA extracorporeal life support in a large prospective international cohort.\n* To compare different strategies to unload the left ventricular in terms of efficacy and outcomes;",[509,510,28],"Shock, Cardiogenic","Cardiac Arrest",[185,512,513,510,514],"Left ventricle unloading","Cardiogenic shock","Mechanical Circulatory Supports","2025-01-03",{"date":517,"type":37},"2025-01-09",{"date":492,"type":37},{"date":520,"type":21},"2026-04-01",{"name":522,"class":44},"Maastricht University Medical Center",{"id":524,"slug":525,"hasResults":11,"nctId":526,"briefTitle":527,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":530,"enrollmentInfo":531,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":533,"conditions":534,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":45},"100462568","monitoring-of-cerebral-blood-flow-in-patients-on-extracorporeal-membrane-oxygenation-100462568","NCT05303363","Monitoring of Cerebral Blood Flow in Patients on Extracorporeal Membrane Oxygenation","NOTICE","Inclusion Criteria: in order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n* High suspicion of an indication for VV-ECMO;\n* Arterial line present to enable blood sampling;\n* Older than 18 years.\n\nExclusion Criteria:\n\n* Subjects will be excluded if the cerebral blood flow cannot be measured using the transcranial Doppler\n* VA-ECMO or ECPR;\n* No possibility for neuromonitoring measurements due to technical difficulties, e.g. post-craniotomy, unsuitable transcranial window;\n* No possibility for neuromonitoring measurements due to circumstantial difficulties, e.g. ECPR;\n* Contraindications for ECMO;\n* ECMO is initiated in another center.","100 Years",{"count":532,"type":21},15,"Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a supportive therapy, indicated in case of severe, possibly reversible pulmonary failure, refractory to conventional therapies. Despite advances, morbidity and mortality remain high. Severe neurological complications can occur during ECMO, but their exact etiology is not well understood. It is hypothesized that fast correction of severe hypercapnia, a common indication for venovenous ECMO, may be detrimental for the brain. The supposed mechanism is that fast correction of hypercapnia may result in massive cerebral vasoconstriction and impaired cerebral blood flow (CBF). In this prospective, observational study the aim is to quantify change in CBF during routine initial correction of severe hypercapnia during VV-ECMO. Furthermore, the investigators will record any other hemodynamic changes during VV-ECMO. The hypothesis is that a larger decline in PaCO2 will result in a larger decline of CBF.",[28,535],"Cerebral Circulatory Failure","2024-08-13",{"date":538,"type":37},"2024-08-15",{"date":540,"type":37},"2021-12-15",{"date":542,"type":21},"2025-08-15",{"name":544,"class":44},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":546,"slug":547,"hasResults":11,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":551,"eligibilityCriteria":552,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":22,"phases":555,"briefSummary":556,"conditions":557,"keywords":560,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":574},"100542090","pharmacokinetics-and-modelling-of-beta-lactam-in-ecmo-va-patients-100542090","NCT06338345","Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients","Pharmacokinetics and Modelling of Beta-Lactam in Patients Undergoing Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO)","KAMELOT","Inclusion Criteria:\n\n* Patients undergoing VA-ECMO\n* Patients requiering initiation of a novel antibiotic therapy with one of the studied beta-lactam (Piperacillin-Tazobactam, Cefepime, or Meropenem) while under VA-ECMO\n* With an expected survival exceeding 24 hours\n* Patient's or their trusted person's consent\n\nExclusion Criteria:\n\n* Subject under administrative or judicial surveillance\n* Non-affiliation to social insurance\n* Pregnant or lactating patient\n* Antibiotic therapy of interest already initiated before VA-ECMO implantation\n* Contraindication to the use of beta-lactam\n* Administration modalities of beta-lactam not compliant with current recommendations\n* Subject in exclusion period from another study",{"count":554,"type":21},225,[24],"The use of antibiotic therapy is common in intensive care units and primarily involves beta-lactams. Its optimal implementation is made difficult by the pharmacokinetic changes inherent in critically ill patients.\n\nDespite the current recommendations from the French Society of Anesthesiology and Intensive Care (SFAR) and the French Society of Pharmacology and Therapeutics (SFPT), there are no recommendations on prescription modalities for patients under veno-arterial extracorporeal membrane oxygenation (VA-ECMO). The use of antibiotic therapy is common in VA-ECMO patients and their pharmacokinetic variability factors are then exacerbated.\n\nWe aim to conduct a prospective, multicenter, interventional study designed to identify predictive factors for failure to achieve therapeutic target circulating concentrations of beta-lactams in patients under VA-ECMO treated with one of the studied beta-lactams",[478,558,510,28,559],"Post-cardiac Surgery","Infections",[319,561,562,563,564],"Infection","Beta-lactam","Pharmacokinetic","Modelling","2024-03-21",{"date":567,"type":37},"2024-03-29",{"date":569,"type":21},"2024-09-01",{"date":571,"type":21},"2028-09-01",{"name":573,"class":44},"University Hospital, Grenoble",5,{"id":576,"slug":577,"hasResults":11,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":99,"eligibilityCriteria":581,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":583,"conditions":584,"keywords":585,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":591,"leadSponsor":593,"locationsCount":45},"100540656","pkpd-study-of-anti-infective-drugs-in-critically-ill-patients-receiving-extracorporeal-membrane-oxygenation-treatment-100540656","NCT06319677","PK\u002FPD Study of Anti-Infective Drugs in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation Treatment","PK\u002FPD Study of Antibiotics in Critically Ill Patients Receiving ECMO","Inclusion Criteria:\n\n1. Written informed consent was obtained from the patient or family member\n2. Patients who are undergoing ECMO or not\n3. Anti-infection treatment indications\n\nExclusion Criteria:\n\n1. Patients under 18 years of age or pregnant\n2. Information on antimicrobial therapy and ECMO support is incomplete\n3. Presence of other circumstances that make participation in this study inappropriate",{"count":395,"type":21},"Extracorporeal membrane pulmonary oxygenation (ECMO) may provide partial or complete support for organ replacement in patients with severe cardiopulmonary failure, buying time for further management of the primary disease. However, ECMO may significantly alter the pharmacokinetic and pharmacodynamic profiles of critically ill patients, affecting the safety and efficacy of drug therapy. This prospective observational study aims to investigate the impact of ECMO treatment on the pharmacokinetics and pharmacodynamics of antimicrobial drugs in critically ill adult patients. Investigators intend to establish a Population Pharmacokinetic (POP PK) and Pharmacokinetic\u002FPharmacodynamic (PK\u002FPD) model by prospectively collecting blood samples from patients and relevant treatment data. The primary objective is to quantitatively characterize the pharmacokinetic profiles of critically ill patients undergoing ECMO support and provide model-based recommendations for drug regimens tailored to critically ill patients.",[97,28],[97,99,586],"Population Pharmacokinetics","2024-03-19",{"date":589,"type":37},"2024-03-20",{"date":141,"type":21},{"date":592,"type":21},"2027-05-01",{"name":594,"class":44},"The Third Xiangya Hospital of Central South University",{"id":596,"slug":597,"hasResults":11,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":601,"eligibilityCriteria":602,"healthyVolunteers":11,"sex":16,"minAge":603,"maxAge":4,"enrollmentInfo":604,"targetDuration":4,"studyType":22,"phases":606,"briefSummary":607,"conditions":608,"keywords":609,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":45},"100492936","distal-perfusion-timing-early-or-conservative-to-prevent-limb-ischemia-during-peripheral-va-ecmo-100492936","NCT05698628","Distal Perfusion Timing, Early or Conservative, to Prevent Limb Ischemia During Peripheral VA-ECMO","Comparison Of Conservative Versus Early Distal Perfusion Strategy to Prevent Acute Limb Ischemia in Peripheral Venoarterial Extracorporeal Membrane Oxygenation Patients","DECIDE-ECMO","Inclusion Criteria:\n\n* Age ≥19 years old\n* Refractory cardiogenic shock with peripheral VA-ECMO\n* Informed consent\n\nExclusion Criteria:\n\n* Unwilling or unable to obtain informed consent from the participant or substitute decision-maker\n* Patients who are currently pregnant, postpartum period within 30 days or are breast-feeding\n* VA-ECMO application for causes other than cardiogenic shock\n* Severe coagulopathy\n* Irreversible limb ischemia requiring interventional procedures or surgery at the time of VA-ECMO (previously diagnosed ASO(atherosclerosis obliterans) patients)","19 Years",{"count":605,"type":21},400,[24],"Peripheral VA-ECMO is widely used in refractory cardiogenic shock patients as a salvage therapy. In most cases, the femoral artery and vein are used for the vascular approach. Large cannulas are usually used for proper oxygenation, which may cause peripheral limb ischemia. Distal perfusion catheterization (DPC) at the ipsilateral arterial cannula site is recommended to prevent distal limb ischemia. However, there is no consensus on the proper timing of DPC and additional invasive procedures may cause complications during VA-ECMO support. In this analysis, the investigators compare the clinical outcomes of distal limb ischemia complications between the conventional DPC group (DPC at the time of limb ischemia sign) and the preemptive DPC group (DPC at the time of VA-ECMO application).",[28],[185,610,513],"Limb ischemia","2023-06-12",{"date":613,"type":37},"2023-06-15",{"date":615,"type":37},"2023-04-28",{"date":617,"type":21},"2027-02-28",{"name":619,"class":44},"Min-Seok Kim",{"id":621,"slug":622,"hasResults":11,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":626,"eligibilityCriteria":627,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":393,"enrollmentInfo":628,"targetDuration":629,"studyType":57,"phases":4,"briefSummary":630,"conditions":631,"keywords":633,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":45},"100387892","post-surgery-extracorporeal-life-support-100387892","NCT04330651","Post-Surgery Extracorporeal Life Support","Outcomes' Predictors in Post-Surgery Extracorporeal Life Support","PC-ECLS","Inclusion Criteria:\n\n* Patients underwent cardiac surgery\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years",{"count":506,"type":21},"20 Years","Extracorporeal Life Support (ECLS) may provide pulmonary and circulatory support for patients with acute heart failure refractory to conventional medical therapy. However, indications and effectiveness of ECLS engagement post-surgery remains a concern. The investigators sought to analyze indications, modality and outcomes of PS-ECLS, to identify predictors of early and midterm survival after PS-ECLS. The investigators have recorded prospectively, and analysed data of 209 consecutive PS-ECLS patients between January 2004 and December 2018. Demographic and clinical data before, during and after PS-ECLS were collected and their influence on hospital mortality and outcomes (early and midterm) will analyse. Multivariate analysis of pre PS-ECLS implantation factors (as age, female sex , insulin-dependent diabetes, pulmonary hypertension, STS, type of surgical procedure data, pre-ECLS blood lactate level) will be made for identify prognostic risk factors of in-hospital mortality. Overall survival will be analysed, at 6 months,1-year and 5-years, respectively and the factors influencing mild\u002Fterm outcome will be investigated.",[478,184,28,632,558],"Post Cardiac Arrest Syndrome",[634,635,636,637,638,639],"extracorporeal life support","ecls","ecmo","outocome","prognostic factors","extracorporeal membrane oxygenation","2021-04-27",{"date":642,"type":37},"2021-04-28",{"date":644,"type":4},"2004-01",{"date":646,"type":21},"2029-01-31",{"name":648,"class":44},"University of Florence"]